Shumway Capital

Shumway Capital, founded in 2002 and based in Greenwich, Connecticut, is an investment firm that specializes in growth-focused investments. The firm leverages the firsthand entrepreneurial experience of its investment team to assist companies in accelerating growth and achieving their objectives. Shumway Capital invests its own capital, providing a permanent financial foundation for its ventures. The firm targets high-growth businesses across various industries, including technology, consumer goods, telecommunications, energy, finance, and healthcare, with a global investment approach. Its collaborative strategy allows management teams to operate effectively without disruptions, fostering a supportive environment for growth and innovation.

Chris Lange

Managing Director, Senior Partner and Head of Investments

Kenneth Palumbo

CFO

11 past transactions

Elligo Health Research

Series E in 2021
Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Vedanta Biosciences

Series D in 2021
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Finch Therapeutics

Series D in 2020
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Finch Therapeutics

Series C in 2019
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Vedanta Biosciences

Series C in 2019
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Elligo Health Research

Series C in 2019
Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Elligo Health Research

Series B in 2018
Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Finch Therapeutics

Series B in 2018
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Artsy

Series D in 2017
Artsy is the largest online art marketplace, offering access to over one million artworks from both iconic and emerging artists, sourced from more than 4,000 galleries, leading auction houses, and prestigious art fairs. The platform aims to expand the art market by supporting artists and promoting art globally. By collaborating with prominent museums and galleries, Artsy enables users to discover, learn about, and collect art. Additionally, the company manages online art publications, further enhancing its role as a comprehensive resource for art enthusiasts and collectors.

Elligo Health Research

Series A in 2016
Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Trumid

Series A in 2015
Trumid Financial LLC is a financial technology company that specializes in electronic trading solutions for the corporate bond market. Founded in 2014 and based in New York City, Trumid operates the Trumid Market Center, an electronic trading network that connects market professionals to a wide array of liquidity sources. This platform enhances trading efficiency through various protocols and an intuitive design that integrates seamlessly into traders' workflows. Trumid also offers Trumid Bond Stream, which provides real-time TRACE pricing data, and Trumid Labs, which utilizes data science to enhance network management and facilitate bond price lookups. Through its innovative technologies and product offerings, Trumid aims to improve transparency, liquidity, and trade execution in the credit trading space.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.